Novartis Hid Manipulated Data While Seeking Approval for $2.1 Million Treatment

The failure to report the issue has not put patients at risk, the F.D.A. said, but the drugmaker could face criminal and civil penalties.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Novartis AG Food and Drug Administration Drugs (Pharmaceuticals) Spinal Muscular Atrophy Genetics and Heredity gene therapy your-feed-healthcare Source Type: news